sameAs
The translesion DNA polymerase theta plays a dominant role in immunoglobulin gene somatic hypermutationEndonuclease G plays a role in immunoglobulin class switch DNA recombination by introducing double-strand breaks in switch regionsToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesA role for DRAK2 in the germinal center reaction and the antibody responseBCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathwayRegulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombinationHoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutationEpigenetics of Peripheral B-Cell Differentiation and the Antibody ResponseRegulation of Aicda expression and AID activityCrystal Structure of a Human Autoimmune Complex between IgM Rheumatoid Factor RF61 and IgG1 Fc Reveals a Novel Epitope and Evidence for Affinity MaturationKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Current status and unanswered questions on the use of Denosumab in giant cell tumor of boneSelective inhibition of class switching to IgG and IgE by recruitment of the HoxC4 and Oct-1 homeodomain proteins and Ku70/Ku86 to newly identified ATTT cis-elementsDCs induce CD40-independent immunoglobulin class switching through BLyS and APRILEfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe HoxC4 homeodomain protein mediates activation of the immunoglobulin heavy chain 3' hs1,2 enhancer in human B cells. Relevance to class switch DNA recombinationImatinib mesylate in chordomaClass switching and Myc translocation: how does DNA break?Regulation of B Cell Differentiation by Intracellular Membrane-Associated Proteins and microRNAs: Role in the Antibody ResponseAdvances and controversies in the management of soft tissue sarcomas.The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.Adjuvant Imatinib for GI Stromal Tumors: When and For How Long?Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.Response to imatinib plus sirolimus in advanced chordoma.Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasSystemic therapy options for unresectable and metastatic chordomas.Phase II study of imatinib in advanced chordoma.Imatinib in advanced chordoma: A retrospective case series analysis.Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapySorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcomaFeasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three VersHistotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
P50
Q24537096-DE917D58-5639-430A-9E9F-D116CA2E0AD8Q24623341-9650C61D-2647-41BC-A378-FCCFC3E64AB8Q24624348-414070E5-C03C-4635-AEB3-CFCD5161F97AQ24630648-B84307A9-DC08-4984-A55F-773E7E73A706Q24632504-2194EBA0-8450-41AC-A7C9-DE0B2AE4C37CQ24633098-428FBC48-BDF5-4219-9EBD-B11D53C07C1DQ24645030-CD619919-EA6A-4238-B1B1-A0F3E722A4B0Q26772330-75158BBA-1B64-45FE-87EF-DFFA02A21FACQ26853622-BD714860-3B93-4031-88FC-F65445A9B71CQ27644278-6BF52C89-308C-42B2-850C-A906232C963AQ27824868-228DBA20-1E02-4795-B625-6C5A95DBE7B1Q27928062-C0E778B3-FB32-4F71-A4BA-16DF02E885ADQ28066533-0338ED72-CA6B-489A-A5B9-0898FD3E2D37Q28188341-DAFDC476-3B9D-4387-88F0-6175C1CA56ABQ28216755-A0B42930-FD2A-4927-AF28-9835F5512983Q28268831-98C8434B-C898-4415-AD5C-8EF122523964Q28271930-ABF06B93-38A3-4D6A-A1FA-F99A778496CBQ28282621-AE942314-4A2F-4E21-A014-5B9A5A2E1B1EQ28288991-B58D0BBC-1D74-49F2-AF99-251C06015DAAQ28608455-7F89209F-832F-491D-9A7B-D5F86B790136Q30240228-90FBF2D0-7F60-4060-9572-515ED88A905CQ30985539-93897B0B-88A7-411B-BB93-E43359506BC6Q33166535-CA317712-E9F1-4270-AC54-3AD0C141F201Q33272734-775B58A1-5DD6-455E-B844-7F8FC90F7890Q33273440-EF12159B-4671-40BF-9407-E03E9EB72D64Q33273555-0EFA66A4-1553-4B30-BB53-DEFDF4C99798Q33273701-DED941D6-5ECA-4641-B623-5BFB5B7671B2Q33274146-58B8BBF1-481A-4892-A7CD-4D62FADA8B56Q33274377-5359DFFF-A022-4078-BB0B-84D4D4239F84Q33275725-8BB7F38B-5B3A-4A89-A092-EA67EB609F57Q33275974-AF7411BA-DDA6-4BA8-A37E-7D7C432E8881Q33276109-8E560979-98DD-440A-A9A4-C8C12524E693Q33276384-D9808494-CF66-4BE2-AA11-7818E8103FB9Q33371397-81E2FCDD-575F-4C88-B8A8-A34574A4722CQ33389496-2404BD95-B409-4CAA-A8A4-3D2309202777Q33416940-314EEE50-A21E-43FD-94A0-F557E905A365Q33419286-26024628-516C-476D-975C-F7013822663EQ33420031-30580E80-DFA5-44FE-AFD0-174B9D80C4B9Q33425709-890C3339-AEC6-4E63-AB75-AEF2EED783B2Q33441802-A009E1BE-7C33-439B-84E3-7AB01DF419FE
P50
description
Italian oncologist
@en
Italian oncologist
@en-ca
Italian oncologist
@en-gb
oncoloog
@nl
oncólogo italiano
@es
طبيب أورام إيطالي
@ar
name
Paolo Giovanni Casali
@ast
Paolo Giovanni Casali
@da
Paolo Giovanni Casali
@de
Paolo Giovanni Casali
@en
Paolo Giovanni Casali
@es
Paolo Giovanni Casali
@fo
Paolo Giovanni Casali
@fr
Paolo Giovanni Casali
@is
Paolo Giovanni Casali
@kl
Paolo Giovanni Casali
@nb
type
label
Paolo Giovanni Casali
@ast
Paolo Giovanni Casali
@da
Paolo Giovanni Casali
@de
Paolo Giovanni Casali
@en
Paolo Giovanni Casali
@es
Paolo Giovanni Casali
@fo
Paolo Giovanni Casali
@fr
Paolo Giovanni Casali
@is
Paolo Giovanni Casali
@kl
Paolo Giovanni Casali
@nb
altLabel
P Casali
@en
P G Casali
@en
P. Casali
@en
P. G. Casali
@en
Paolo Casali
@en
Paolo G Casali
@en
Paolo G. Casali
@en
prefLabel
Paolo Giovanni Casali
@ast
Paolo Giovanni Casali
@da
Paolo Giovanni Casali
@de
Paolo Giovanni Casali
@en
Paolo Giovanni Casali
@es
Paolo Giovanni Casali
@fo
Paolo Giovanni Casali
@fr
Paolo Giovanni Casali
@is
Paolo Giovanni Casali
@kl
Paolo Giovanni Casali
@nb
P1053
D-1524-2017
P1153
36870765400
P21
P214
4746148876460149740006
P31
P3829
P496
0000-0003-4056-8023
P735
P7859
viaf-4746148876460149740006